Pipeline
DKN-01:Anti-DKK1 antibody
tislelizumab + chemotherapy
Preclinical
Phase 1
Phase 2
Phase 3
- Gastric
DKN-01:Anti-DKK1 antibody
bevacizumab + chemotherapy
Preclinical
Phase 1
Phase 2
Phase 3
- Colorectal
DKN-01:Anti-DKK1 antibody
pembrolizumab
Preclinical
Phase 1
Phase 2
Phase 3
- Endometrial
FL-301 (NBL-015):Anti-CLDN18.2 antibody
Preclinical
Phase 1
Phase 2
Phase 3
- Gastric
- Pancreatic
FL-302 (NBL-016):Anti-CLDN18.2/CD137 antibody
Preclinical
Phase 1
Phase 2
Phase 3
FL-501:Anti-GDF15 antibody
Preclinical
Phase 1
Phase 2
Phase 3